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The Epstein-Barr virus BamHI-F promoter (Fp) is one of three used to transcribe the EBNA latency
proteins, in particular, EBNA-1, the only viral gene product needed for episomal replication. Fp is
distinguished by possession of the only EBNA-1 binding sites (the Q locus) in the Epstein-Barr virus genome
outside oriP. Activity of Fp is negatively autoregulated by interaction of EBNA-1 at two sites in the Q locus,
which is situated downstream of the RNA start site. We demonstrate in transient assays that this
EBNA-1-mediated repression of Fp can be overcome by an E2F transcription factor which interacts with the
DNA at a site centered between the two EBNA-1 binding sites within the Q locus. An E2F-1 fusion protein
protects the sequence 5'-GGATGGCGGGTAATA-3' from DNase I digestion, and a DNA probe containing this
sequence binds an E2F-specific protein complex from cell extracts, although this region is only loosely
homologous with known consensus binding sites for E2F transcription factors. In mobility shift assays, E2F
can displace the binding of EBNA-1 from the Q locus but not from oriP, where the E2F binding site is not
present. E2F also activates expression of Fp in epithelial cells. These findings identify a potentially new binding
site for members of the E2F family of transcription factors and suggest that such a factor is important for
expression of EBNA-1 in lymphoid and epithelial cells by displacing EBNA-1 from the Q locus. In addition, the
possibility that Fp activity is under cell cycle control is raised. Since the supply of functional E2F varies during
the cell cycle and since in these assays overexpression of E2F can overcome repression of Fp by EBNA-1,
control of transcription of EBNA-1 mRNA by cell cycle regulatory factors may help to bring about ordered
replication of episomes.
Epstein-Barr virus (EBV) is associated with the develop-
ment of malignancies (lymphomas and carcinomas of the
nasopharynx) in both of the cell types it infects (10, 45, 59). In
each of these tumors, the viral genome exists as a circular
episome, characteristic of EBV latency (42). The key gene
required for initiation and maintenance of latent infection
encodes Epstein-Barr nuclear antigen 1 (EBNA-1). By binding
to specific repeated DNA sequence motifs at the origin of
plasmid replication (oriP) (38), EBNA-1 activates both episo-
mal replication and the oriP transcriptional enhancer (46, 47,
60, 65) and thus acts as a positive regulatory protein.
In type 1 Burkitt's lymphoma cells, as well as in nasopha-
ryngeal carcinoma, the EBNA-1 transcript arises from Fp, a
promoter in the BamHI-F fragment of the EBV genome (31,
49, 50, 52, 58). The major RNA start site for Fp lies 200 bp
upstream of two imperfect yet functional binding sites for the
EBNA-1 protein (the Q locus), the only other location for
EBNA-1 binding sites in the EBV genome (1, 29, 46). Expres-
sion of Fp is negatively autoregulated by EBNA-1 acting
through the Q locus (51, 62). This EBNA-1-mediated repres-
sion can be transferred to a heterologous promoter and only
requires one EBNA-1 binding site (62). The strong autorepres-
sion of Fp by EBNA-1 raises the question of how Fp can be
activated in EBV-infected cells, all of which express EBNA-1.
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In this paper, we show that while Fp is repressed by EBNA-1,
it can also be activated by an E2F-like transcription factor
which binds to DNA within the Q locus and that the activity of
the promoter is reciprocally regulated by these cellular and
viral proteins.
MATERUILS AND METHODS
Cell lines. Raji (44) is a latently infected EBV-positive
Burkitt's lymphoma B-cell line, and Jurkat is an EBV-negative
human T-cell line. SVK is a human keratinocyte cell line (35).
All cells were maintained at 37°C in a 5% CO2 environment.
Lymphoid cells were grown in RPMI medium supplemented
with 10% fetal calf serum.
Recombinant phagemid constructs. A series of phagemid
constructs, pFl, pF2, pF3, pF4, pF2x, pF12, pF13d, and pF13,
containing various amounts of sequence flanking the Fp RNA
start site, were generated by PCR amplification of genomic
DNA from the B95-8 cell line, using primers specific for the Fp
region. 5' and 3' primers contained HindIII and XbaI adapters,
respectively. The resulting PCR products were then inserted 5'
of the chloramphenicol acetyltransferase (CAT) gene in the
phagemid vector pBSCAT (16) (Fig. 1A). The sequences
included in constructs pFl, pF2, pF3, pF4, and pF2x, relative
to the RNA start site (50, 52), are shown in Fig. 1A, and those
for constructs pF12, pF13d, and pF13 are shown in Fig. 2.
Construct pQEco was generated by two-step PCR of a pF13
DNA template. Degenerate oligonucleotide primers were used
to mutate 3 bp within the region of the Q locus protected from
DNase I digestion by the glutathione S-transferase (GST)-
RBP-3 fusion protein. The footprinted sequence was changed
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FIG. 1. Schematic representation of F promoter constructs used in
transient-transfection assays. (A) RNA start site for Fp, as determined
by Sample et al. (50) and Schaefer et al. (52), represented as a bent
arrow. Q-locus (filled circles), the two low-affinity binding sites for the
EBNA-1 protein. Promoter constructs are shown below, with coordi-
nates relative to the RNA start site. Each was linked to the CAT gene
in phagemid vector pBSCAT (16). (B) Constitutive activity of Fp
constructs in EBV-negative Jurkat cells. Promoter activity is shown as
average percent acetylation. (C) Constitutive activity of Fp constructs
in EBV-positive Raji cells.
to 5'-CTACCGAATCCGGGTAATA-3'; mutated bases are
underlined.
The constructs pRSV Ela Neo and pRSV Ela928 Neo were
generous gifts from David Johnson of Joseph Nevins' labora-
tory. The former consists of a pRC Rous sarcoma virus vector
(Invitrogen) which expresses wild-type ElA protein, and the
latter has the same vector backbone but expresses mutant ElA
which cannot bind to Rb and therefore cannot release E2F
(27a).
The CMV-RBP-3 construct, kindly provided by K. Helin,
contains the cDNA encoding amino acids 88 through 437 of
the E2F-1 transcription factor under the control of the cyto-
megalovirus (CMV) immediate-early (IE) promoter (22). The
pHD101-3 vector, containing the CMV-IE promoter in a
pGem-2 plasmid, was used as a negative control (13).
DNA transfections. Plasmid DNA was amplified in Esche-
richia coli and purified through Qiagen columns. For each
sample, 10 ,ug of plasmid DNA was electroporated (40) into
1 X 107 lymphoid or 0.5 x 107 epithelial cells at 1,500 V, using
the University of Wisconsin Zapper electroporation unit. Cells
were then suspended in 5 ml of RPMI 1640 medium supple-
mented with 10% fetal calf serum and incubated for 48 h at
37°C in 5% CO2.
CAT assays. Extracts were prepared by washing cell pellets
twice in phosphate-buffered saline solution (PBS), resuspen-
sion in 200 ,ul of 0.25 M Tris-HCl (pH 7.5), and four cycles of





FIG. 2. E2F-1 activates Fp in transient promoter assays. Five
micrograms of each promoter construct was cotransfected with 5 ,ug of
either CMV-RBP-3 or pHD101-3, a negative control vector, into the
EBV-positive cell line Raji (A) and into the EBV-negative human
keratinocyte line SVK (B). Schematic representations of constructs
pF12, pF13d, and pF13 are shown below. pE2CAT, a positive control
for E2F responsiveness, contains the adenovirus E2 promoter linked to
the CAT gene. Results are expressed as the relative promoter activity
in the presence and absence of CMV-E2F-1.
ously t18), by incubating each sample with acetyl coenzyme A
and [l C]chloramphenicol at 37°C for 2 h. Acetylated reaction
products were separated by thin-layer chromatography, visual-
ized by autoradiography, and quantitated by scintillation
counting or by scanning on a Molecular Dynamics Phospho-
rImager. Percent acetylation is calculated as the ratio of counts
per minute in the acetylated reaction products to counts per
minute in the entire sample, and fold activation is calculated as
the percent acetylation relative to a negative or positive control
value.
Preparation of 32P-labelled probes for mobility shift assays.
DNA probes were generated by annealing oligonucleotides
spanning the regions of interest and filling in any single-
stranded overhang with the Klenow enzyme. Probes were end
labelled with polynucleotide kinase and are diagrammed in
Fig. 3A, 5A, and 7A.
Preparation of whole-cell extracts. Approximately 108 cells
were washed with PBS and resuspended in extraction buffer
containing 20 mM N-2-hydroxyethylpiperazine-N'-2-ethane-
sulfonic acid (HEPES), 450 mM NaCl, 0.2 mM EDTA, 25%
glycerol, 0.5 ,ug of leupeptin per ml, 1 ,ug of aprotinin per ml,
0.5 ,ug of pepstatin per ml, and 0.5 ,uM dithiothreitol (DTT).
Extracts were then sonicated on ice for 10 short bursts, and
debris was removed by centrifugation at 12,000 x g for 20 min
at 4°C. Aliquots of the supernatant fluids were stored at
-70°C. Protein determinations were done with the Bradford
protein assay.
Preparation of GST fusion proteins. The GST-RBP-3 con-
struct, containing amino acids 88 through 437 of the E2F-1
transcription factor, was provided by K. Helin (22). The
full-length, wild-type GST-E2F-1 construct and the GST-
E2F-1 DNA-binding mutant, pGEX2T-E2F-1 Ecol38, were
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The GST-EBNA-1 construct was made by inserting an RsaI-
MscI DNA fragment, which contains the EBNA-1 open read-
ing frame minus the first seven amino acids and the Gly-Ala
repeats, into the SmaI site of pGEX 1N (57). Overnight
cultures of E. coli transformed with this plasmid were induced
with 0.1 mM isopropyl-p-D-thiogalactopyranoside (IPTG) for 3
h. Induced cultures were pelleted, lysed in a 1% Triton X-100
solution, and sonicated. GST-EBNA-1 fusion protein was
purified by incubating the lysate with glutathione-agarose
beads. Following three washings with PBS, purified fusion
protein was eluted with 5 mM reduced glutathione in 50 mM
Tris-HCl (pH 8.0).
Gel mobility shift assays. Binding reactions with whole-cell
extracts contained 25 mM Tris (pH 7.5), 125 mM NaCl, 1.25
mM DTT, 12.5% glycerol, 0.05 mg of sonicated salmon sperm
DNA per ml, 0.06% Nonidet (NP-40), 6.25 mM MgCl2, and
0.06 mg of bovine serum albumin (BSA) per ml. After prein-
cubation for 5 min at 22°C, 25,000 cpm of radiolabelled probe
was added, and the mixture was incubated for 20 min at 22°C.
Samples were then electrophoresed at 4°C through nondena-
turing polyacrylamide gels in lx Tris-borate-EDTA buffer.
Protein-DNA complexes were visualized by autoradiography.
For the supershift reactions, binding reaction mixtures con-
taining whole-cell Jurkat extracts were incubated on ice with
0.5 RI of either monoclonal antibody to E2F (KH95; contrib-
uted by Nick Dyson and Ed Harlow) (23) or EBNA-1 (EB-
NA.OTxl; contributed by J. Middeldorp) (7) for 1 h before the
addition of radiolabelled probe.
Binding mixtures for the displacement mobility shift assays
were solutions of 20 mM Tris-HCI (pH 7.5), 100 mM NaCl, 1
mM DTT, 0.05 mg of sonicated salmon sperm DNA per ml,
10% glycerol, 0.5% NP-40, and 5 mM MgCl2. One microgram
of purified GST-EBNA-1 was incubated with 5,000 cpm of
labelled Qd for 15 min to allow binding. Subsequently, purified
GST-E2F-1, GST-E2F-1 DNA-binding mutant, GST-Z, or
GST was added and incubated for an additional 20 min.
Gel shift competitors. All competitors for the gel mobility
shift assays were annealed oligonucleotides that were purified
by phenol-chloroform extractions and passed through a G-25
column (Boehringer-Mannheim), except for the thymidine
kinase (TK) competitor (a gift from David Johnson in Joseph
Nevins' laboratory). The sequences for the oligonucleotides are as
follows: human dihydrofolate reductase promoter (DHFR),
5'-CCACAATTTCGCGCCAAACTTGAC-3', adenovirus






one binding site from the adenovirus E2 promoter (E2F),
5'-AATFTTGAGAAAGGGCGCGAAACTAGTC-3'; and the
mutant control for E2F (E2Fm), 5'-AAT'TTGAGAAACTA
GAGTCTGCTAGTC-3' (reviewed in reference 41).
DNase I footprinting. A DNA probe, radiolabelled on the
noncoding strand, was prepared by digesting the pQa plasmid
construct, which contains Fp sequences from +134 to +307
cloned into the XbaI site of the pBSCAT vector, with HindIII
and PvuII. The resulting fragment, which contained Fp se-
quences from + 134 to +260, was gel purified and filled in with
radiolabelled nucleotides, using the Klenow enzyme. Binding
reaction mixtures contained 7 mM MgCl2, 1 ,ug of sonicated
calf thymus DNA per ml, 0.14 ,ug of BSA, 0.75% NP-40, 4 mM
HEPES (pH 7.6), 8 mM KCl, 0.02 mM ethylene glycol-bis(p-
aminoethyl ether)-N,N,N',N'-tetracetic acid (EGTA), 0.5 mM
EDTA, 0.4 mM DTT, and 8.3% glycerol. Following incubation
at 22°C for 20 min, 0.15 U of DNase I (Promega) was added for
1 min. Digestion was stopped by the addition of a solution
containing 100 mM NaCl, 100 mM Tris-Cl (pH 8.0), 20 mM
EDTA (pH 8.0), 0.1% SDS, 100 jig of proteinase K per ml, and
100 jig of glycogen per ml. Reaction products were extracted
with phenol-chloroform, ethanol precipitated, electrophoresed
on a 6% polyacrylamide-urea denaturing gel, and visualized by
autoradiography.
RESULTS
Constitutive activity of Fp in infected and uninfected lym-
phoid cells. To study promoter activity, a set of phagemid
constructs containing various amounts of DNA sequence
flanking the Fp RNA start site was made. Promoter inserts
were generated by PCR amplification of genomic DNA from
the B95-8 strain of EBV and linked to the CAT gene in the
phagemid vector pBSCAT (16). Constructs shown in Fig. 1A
were transfected by electroporation into different cell lines,
and promoter activity was gauged by CAT assay.
When constructs pFl through pF4 were transfected into the
EBV-negative Jurkat cell line, Fp was constitutively active
(Fig. 1B). When the constructs were transfected into the
EBV-positive Raji cell line, however, promoter activity was
completely abolished in those constructs which contained the
downstream Q locus, to which EBNA-1 binds with a low
affinity (Fig. 1C). This result confirms that a factor present in
EBV-infected cells, presumably EBNA-1, acts to repress Fp
activity through interaction with the consensus binding sites
downstream of the Fp transcriptional start site (51).
Promoter construct pF2x, which contained just 5 bp of
downstream sequence, was far less active than constructs pFl
and pF3, which contained 190 bp of downstream sequence
(Fig. 1B and C), in both infected and uninfected cells, suggest-
ing the existence of a downstream positive regulatory element
located between +5 and + 190.
E2F-1 activates Fp in transient promoter assays. To deter-
mine whether a known cellular factor might serve to activate
Fp, the DNA sequence of the downstream region was scanned
for known transcription factor binding sites. No perfect match
was found; however, a sequence resembling the consensus
binding site for the E2F-1 transcription factor was identified
within the downstream positive regulatory region, between
nucleotides +172 and +181 relative to the RNA start site
(TllTGCGAAAA). As shown in Fig. 2A, the pF13 construct
normally under EBNA-1 repression in EBV-infected Raji cells
was activated an average of 26-fold when cotransfected into
Raji cells with the CMV-RBP-3 plasmid, which expresses the
E2F-1 protein under the control of the CMV IE promoter. In
addition, in the human keratinocyte cell line SVK, pF13
showed an average of 8.6-fold activation. Interestingly, CMV-
RBP-3 did not transactivate the shorter constructs, pF12 or
pFl3d, both of which contained the suspected positive regula-
tory region. Unexpectedly, therefore, the E2F-responsive re-
gion of Fp appears to lie within the Q locus (+190 to +307)
rather than in the region from +5 to + 190. Moreover, the
E2F-responsive region is functional in epithelial as well as
lymphoid cells.
A fusion protein expressing the E2F-1 transcription factor
binds specifically to the F promoter. To determine whether the
E2F-1 protein interacted directly with DNA sequence in the F
promoter region (Fig. 3A),, mobility shift assays were per-
formed with purified GST-RBP-3 fusion protein, kindly pro-
vided by K. Helin (22). This fusion protein formed three
complexes with the Qa probe, which extends from + 134 to
+ 307, and encompasses both the positive regulatory element
MOL. CELL. BIOL.
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FIG. 3. Interaction of an E2F7-1 fusion protein with the Fp down-
stream regulatory region. (A) DNA sequence of probes and compet-
itors used in mobility shift assays. (B) Labelled DNA probes shown
were incubated with either GST protein (lanes 1, 8, and 13) or with
GST-RBP-3 protein (lanes 2-7, 9-12, and 14). UV-21 is a DNA probe
derived from the mouse major histocompatibility complex class II
regulatory region and contains an NF-KB site (53).
identified earlier and the Q locus (Fig. 3B, lane 2). Formation
of these complexes was specifically inhibited with a 100-fold
excess of unlabelled E2F-binding probe (Fig. 3B, lane 6) but
not by a 100-fold excess of E2Fm (Fig. 3B, lane 7), which
contains a mutated E2F-binding site that abolishes binding of
E2F. These complexes were also specifically inhibited with a
100-fold excess of unlabelled Qa and Qd probes (Fig. 31B, lanes
3 and 5; probes diagrammed in Fig. 3A) but not by the Qc
probe (lane 4).
As expected, the GST-E2F-1 fusion protein formed com-
plexes with a labelled probe (E2F) containing a consensus
E2F-1-binding site (Fig. 3B3, lane 9); a 100-fold excess of
unlabelled E2F and Qd probes competed with complex forma-
tion (Fig. 31B, lanes 10 and 12), but E2F7m did not (Fig. 3B, lane
11). The GST-E2F-1 fusion protein did not interact with a
nonspecific DNA probe, UV21, containing an NF-KB binding
site (Fig. 3B, lanes 13 and 14) (53).
Although the Qd probe does not contain a perfect consensus
E2F-1 binding site, these results indicate that it is able to
interact directly and specifically with the E2F-1 fusion pro-
tein generated by GST-RBP-3. In addition, E2F-Qa complex
formation is not inhibited with the Qc oligonucleotides, a
result that correlates with the functional data in Fig. 2 and
suggests that the E2F-responsive region of Fp is within the Q
locus.
An E2F-1 fusion protein interacts at a site centered between
the EBNA-1 binding sites in the Q locus. The interaction of
E2F-1 with the Qa probe was localized by DNase I footprint-
ing. As shown in Fig. 4, binding of GST-RBP-3 to the Qa
probe specifically protected a region extending from +214 to
+235 relative to the RNA start site of Fp (50, 52). Interest-
ingly, this region is only loosely homologous to known consen-
sus binding sites for E2F-1. Furthermore, the E2F-1 footprint
overlaps with parts of the two low-affinity binding sites for the
EBNA-1 protein that define the Q locus. An area of incom-
plete protection extending from + 191 to +204 was also
CO
0 0







se;Ifg of EF bIng i
+260,relative to the Fp RNAsat sie was diese wihDNs
GST-RBP-3 (lane 4).Lane1 conaina. adro haepoe
Protecteds uec isNce
reuaoyeemn ewe ncetds+ 134 an F10
The. Q.locusebInd anotp2Fntike protebndngincompex in whole-cellm
exreuacts.yTwgonsp eificeleproteicopexeswrteneigrate whent
the60dpreltvobtewas RNincuarsiewadgstedwithwhleclletrcsefro
Jurkatin icllb(ataowtnotshowen).anTwo prbSTthateispanned theo
fooTpRinted portins)ae1cntisaGldeof theQdmprobe,.e(29to+25n
exratctsd inqmobility shift assy (Fig.ht.NulethdesQnlued probhe
formed oineinspeificar baned(i. SB,v lane 2)dthate cnadtoualdb
minhiiedwlwotpinth. 0-odecs fsef(i.S,ln)
adetcold. comepectitor from the Efusitesonadt,thehuma c-mycn
promtern andnthadnvrsEpromoter(Fig.nc SB,lhowsrane7oitv
reuand8,ryespetiely) Ietwcoulbeclompeted to3 some extet0b
TheE2 sitesfromsthe humanlike promterncmpe(ig.SBwhlae-c5),
butrnotsbyothecEFites fromei thmpexDHF peromotnerae(FigeSB
lane 6). Introewstingly,awen only wone-e2F siextatfromth
Jradenovirs E2apromoteshwas)se (FigSrb,s lhane 4),nitdcom-
peted18poory Oct-i andg SPA),ioucetiewereuscbaedwihJrasel
noregaiv controspcfcbn(Fig. SB,lanesn 10, rsetivecoly) Asea
additionld conptrtol, afaelerobe cotanngoeE2Fsitesithhuac-y
fromoeanthe adenovirus E2 promoterwasinibite SBy alaofethe
bu o yteE2Fsitesdecibdaovea whel asFpartialyoyter (data not
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suggested that a 100-fold excess of E2 was sufficient to compete
with Qe (data not shown).
In order to confirm the presence of E2F in the complex with
Qe, a specific monoclonal antibody to E2F, KH9S (23), was
used. The antibody supershifted the Qe complex as well as the
complex on the E2F probe (Fig. SC, lanes 1 and 3, respective-
VOL. 14, 1994
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competitor: - Ge E2F TK DltFR c-myc E2 SP-1 Oct-1
2.-.<'Ss.->'-". ;~~~~~~~~~~~N , ' SXS' ,~~~~~~~~~~~~~~~.. --'................
1 2 3 4 l 6 7 8 9
probe tE2rFbv-t
FG AEY1lkcopeinwhole-cellextracts.B)ThbinimlQdpoewsicbted wthe
either no protein (lane 1) or 10 pLg of Jurkat whole-cell extracts (lanes
2 to 10) and inhibited with 200-fold excess E2 sites from various
promoters. E2F complex is indicated by the arrow. (C) Labelled Qe
probe (left panel) orE: probe (right panel) was incubated with 10
of whole-cell extracts from Jurkat cells and 0.5 pAi of a monoclonal
antibody to either E2F (lanes 1 and 3) or EBNA-1 (lanes 2 and 4).
Arrowhead indicates the supershifted band.
ly). The complexes on the Qe or the E2F probe were not
supershifted by EBNA-1 monoclonal antibody EBNA.OTxl
(7).
The footprinting studies revealed another region of interac-
tion with E2F (+191 to +204). A probe, Qf (Fig. 5A), con-
taining this site also formed a specific band when incubated
with Jurkat extracts (Fig. 6, lane 2). This complex bound with
reduced affinity, as suggested by footprinting data, and was
inhibited with Qe and E2F sites from the E2 promoter (Fig. 6,
lanes 5 and 6, respectively). Therefore, our results indicate that
there are two distinct sites in Fp which bind E2F. The DNA
sequences of these regions had hitherto not been described as
conventional E2F-binding sites.
1 2 3 4 5 6 7
FIG. 6. An E2F transcription factor in whole-cell extracts binds to
Qf. Qf probe (Fig. 5A) was incubated with either no protein (lane 1)
or with 20 ,ug of whole-cell extract from uninfected Jurkat cells (lanes
2 to 7). Oligonucleotide competitors (200-fold excess) were as indi-
cated. E2F complex is indicated by the arrowhead.
An E2F-1 fusion protein displaces EBNA-1 binding from the
Q locus but not from oriP. As demonstrated, E2F-1 activates
Fp in transient promoter assays. Furthermore, the major
E2F-1 DNase I footprint lies between, and partially overlaps,
the two EBNA-1 sites within the Q locus. Therefore, the ability
of E2F to displace EBNA-1 binding from the Q locus was
investigated by mobility shift assays. A purified GST-EBNA-1
fusion protein formed a specific complex with the Qd probe
(Fig. 7B, lane 5). A purified, full-length GST-E2F-1 fusion
protein also formed a specific complex with a mobility different
from that of the GST-EBNA-1 complex (Fig. 7B, lane 4). The
addition of increasing concentrations of the GST-E2F-1 fusion
protein to prebound GST-EBNA-1 caused a displacement of
GST-EBNA-1 from the Qd probe and the formation of the
E2F complex (Fig. 7, lanes 6 to 10). As expected, a GST-E2F-1
mutant that is unable to bind DNA (lane 3) did not displace
the EBNA-1 complex (lane 11). GST and a GST-Z fusion
protein, used as negative controls, were also unable to displace
prebound GST-EBNA-1 (lanes 12 and 13, respectively). These
results suggest that an E2F transcription factor displaces
EBNA-1 by binding to sequences centered between the two
EBNA-1 binding sites in the Q locus.
As shown in Fig. 7A, within the E2F-footprinted region is a
15-bp sequence that is unique to the Q-locus probe (boldface
line above sequence); partly protected sequence is indicated by
the thin line. This 15-bp element is found nowhere among any
of the 24 EBNA-1 binding sites within oriP. This was confirmed
by the inability of GST-E2F-1 to bind to oriP (Fig. 7B, lane
18). The ability of E2F-1 to displace EBNA-1 from oriP was
examined as a further control. GST-EBNA-1 formed a specific
complex with the oriP probe (Fig. 7B, lane 17) and was not
displaced by the addition of GST-E2F-1 (Fig. 7B, lane 15).
This result indicates that E2F recognizes sequences specific to
the Q locus. Furthermore, the displacement of EBNA-1 from
the Qd probe by E2F is specific to sequences contained in the
Q locus.
Point mutations within the E2F-1 binding element abolish
E2F responsiveness. To confirm that E2F responsiveness could
be mediated by DNA sequence within the Q locus, three point
mutations were introduced into the DNase I-footprinted re-
gion (5'-CTACCGAATTACCGGGTAATA-3'; mutated bases
are underlined). This mutated construct, pQEco, which did not
form an E2F complex with Jurkat cell extracts (data not
shown), displayed constitutive activity comparable to that of
- Of Qd Oe E2 Octl
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TABLE 1. Effects of mutation of the E2F binding site on activation
of Fp and activation of repressed Fp by endogenous E2F
Activation (fold) of following cotransfected
Promoter expression construct0:
construct
pCMV-RBP3 pRSV Ela wt pRSV E1a928
pQEco 2.25 ± 0.43 ND ND
pF13 30.3 ± 14.52 3.9 ± 1.0 1.3 ± 0.6
a In the first column, 5 ,ug of each promoter construct, pF13, containing
wild-type (wt) sequences, and pQEco, containing three point mutations in the
DNase I-footprinted region of Fp, was cotransfected in Raji cells with 5 Fig of
pCMV-RBP3 (wild-type E2F-1). Results are presented as fold activation above
that resulting from cotransfection with pHD101-3 (negative control vector). In
the next two columns, Jurkat cells were transfected with 3 p.g of pF13, 0.5 ,ug of
pCMV-EBNA-1 and 6 ,g of pRSV Ela (wild-type E1A) or pRSV Ela9g (ElA
Rb binding mutant). Results are presented as fold activation above that resulting
from cotransfection with pCMV-EBNA-1 and pHD101-3, the negative control
vector.
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FIG. 7. E2F displaces EBNA1 binding from the Q locus but not
from oMP. (A) Sequences of probes used for mobility shift assays. Bars
indicate the two E2F footprinted regions (+ 191 to +204 and +214 to
+235) of the Qd probe. Boxed regions indicate EBNA-1 binding sites.
(B) Qd was used as a probe in the left-hand panel (lanes 1 to 14). A
total of 1 ,ug of GST-EBNA-1 was allowed to bind to Qd (lanes S to
13) for 15 min. GST-E2F-1 (0, 1, 2.5, 5, 10, and 25 ,ug) was then added
to lanes 5, 6, 7, 8, 9, and 10, respectively, and allowed to bind for 20
min. As controls, 25 ,ug of GST-E2F-1 DNA-binding mutant (lane 11),
GST (lane 12), or GST-Z (lane 13) was added and allowed to bind for
20 min. As further controls, 5 p,g of GST (lane 2), 25 ,ug of a
GST-E2F-1 DNA-binding mutant (lane 3), 5 jig of GST-E2F-1 (lane
4), and 25 ,ug of GST-Z (lane 14) were incubated with Qd. A probe
containing two EBNA-1 binding sites from oniP was used in the
right-hand panel (lanes 15 to 18). GST-EBNA-1 (1 ,ug) was allowed to
bind to oriP (lanes 15 to 17) for 15 min, after which 25 ,ug of
GST-E2F-1 (lane 15) or GST-E2F-1 DNA-binding mutant (lane 16)
was added and allowed to bind for 20 min. As a control, 25 jg of
GST-E2F-1 was incubated with oriP (lane 18).
the wild-type construct, pF13, in EBV-negative Jurkat cells
(data not shown), and in EBV-positive Raji cells it was
completely repressed, as expected. Unlike the wild-type pF13
construct, however, the mutant pQEco construct was not
significantly activated by cotransfected CMV-RPB-3 (Table
1), confirming that the nucleotides within the DNase I foot-
print are indeed important for E2F responsiveness of Fp.
ElA activates Fp in transient transfections. E2F is inactive,
existing as part of a heteromeric complex that includes Rb,
until it is dissociated from the complex (41). The adenovirus
protein ElA can disrupt the interaction between E2F and Rb,
thereby allowing E2F to activate responsive promoters. To
show that endogenous levels of E2F were sufficient to upregu-
late Fp, an expression construct of ElA was cotransfected with
pF13 and pCMV-EBNA-1 into Jurkat cells. Overexpression of
ElA repeatedly resulted in 3.9-fold (+ 1.0-fold)-greater acety-
lation than pF13 plus EBNA-1 alone (Table 1). Activation by
ElA was specific because a mutant construct of ElA, which is
incapable of disrupting the Rb-E2F complex, repeatedly
showed only 1.3-fold (+0.6-fold) activation.
DISCUSSION
The EBNA proteins are transcription factors essential for
latent infection and cell immortalization. The recently discov-
ered F promoter, one of three now known to govern transcrip-
tion of the EBNA proteins, is unique in possessing EBNA-1
binding sites. Promoter activity arising from the BamHI-F
region of EBV is negatively autoregulated when the EBNA-1
protein interacts with its low-affinity binding sites in the Q
locus (51, 62). This result raises the questions of when and how
Fp is activated in EBV-infected cells, all of which express
EBNA-1, a protein essential for the persistence of latent EBV
infection. Recently it has become increasingly clear that EBV
gene expression is often regulated by a composite of interactive
viral and cellular factors (19, 30, 33, 36, 48, 55, 56, 61, 66). In this
work, we demonstrate that a member of the E2F family of
transcription factors can overcome the EBNA-1-mediated repres-
sion by interacting directly with DNA within the Q locus. Fur-
thermore, a GST-E2F-1 fusion protein can displace GST-
EBNA-1 bound to the Q locus in mobility shift assays.
Autoregulation of Fp during type 1 latency would permit the
virus to maintain a minimum threshold level of EBNA-1. Low
levels of EBNA-1 would presumably be sufficient to activate
the oiP, to which it binds more abundantly, cooperatively, and
with a higher affinity (1), before binding to the lower-affinity Q
sites and shutting down expression of EBNA-1 from Fp. With
the development of type III latency, in which all EBNAs are
expressed, Fp would remain inactive and promoter usage for
the EBNAs would switch to Cp or Wp (31, 49). EBNA-1
autoregulation could therefore account for the inactivity of Fp
in type III latency.
Adding to this model is our finding that a member of the
E2F transcription factor family interacts with the Q locus and
can overcome the EBNA-1-mediated repression of Fp in
infected cells. The E2F transcription factor, first identified by
its abilities to bind to and to activate the adenovirus E2
promoter (32), is important in the regulation of cellular genes
required for DNA synthesis and replication, such as DHFR,
TK and DNA polymerase ao (5, 14, 24, 43), as well as genes
involved in cell growth, such as c-myc, Cdc2, and cyclin A (12,
26, 39, 41, 63). During the G, phase of the cell cycle, E2F-like
factors are inactive, existing as a part of heteromeric protein
complexes that include the retinoblastoma (RB) protein (3, 4,
6, 9, 15, 21, 25). Upon entry into S phase, E2F dissociates from
the RB protein and is free to activate its target promoters (2,
8, 37).
Because the EBV episome is maintained during latency at a
constant copy number and is replicated coordinately early in S
phase in the cell cycle, and since EBNA-1 is the only viral
protein required for episomal replication, it is likely that
expression or function of EBNA-1 is under cell cycle control.
As more activated E2F becomes available in the cell at the
G1/S boundary, it could activate Fp by displacing EBNA-1
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the Q locus, since in our assays E2F-1 clearly does not interact
with the higher-affinity EBNA-1 binding sites within oriP. The
newly expressed EBNA-1 could then activate latent episomal
replication and coordinately populate the progeny cells with
episomes. This type of regulation, which would allow the virus
to maintain the episome without expressing all of its latent genes,
is consistent with current models for type 1 latency (31, 49).
It has also been suggested that Fp is activated following
induction to the cytolytic phase of EBV infection (34). While
our current results do not directly address this issue, it has been
known for years that induction of lytic viral replication follows
entry into S phase (20). If Fp is indeed active during the lytic
phase of EBV infection, its activity may be triggered, at least in
part, by the higher levels of active E2F available in the cell at
the start of S phase (28, 54). Clearly, the potential cell cycle
control of this promoter deserves further investigation. The
E2F activity we have characterized is of considerable interest
because of the potentially two new binding sites we have
identified. Possibly, both sites work cooperatively to activate
Fp. E2F exists as a family of transcription factors (8, 17, 27),
but only narrow variations on a single consensus binding site
have been tolerated in binding assays (41). Thus, it has not
been possible to identify other promoters that E2F may
activate. Although the exact contact points of the E2F factor
binding in the Q locus have not yet been precisely identified,
the 15-bp sequence we have mapped by DNase footprinting
(5'-GGATGGCGGGTAATA-3') should prove useful in a
number of cell biologic contexts. Our results suggest that an
E2F-1-like protein is involved in the regulation of Fp. In
mobility shift assays, the complex bound to Qe is inhibited by
some E2F binding sites but not others, whereas a complex
formed with the previously described E2F site from the E2
promoter (E2F) is inhibited by all sites. On the basis of
mobility shift assays, it appears that the repression of Fp is
overcome by displacement of EBNA-1 by E2F. In additional
work, an E2F mutant, impaired in its transactivation domain
(28), could only partially overcome EBNA-1 repression in
transient-transfection assays (data not shown). This result
suggests that the transactivation domain may contribute to
overcoming Fp repression.
The discovery (51, 52, 58) and characterization of this new
promoter illustrate the complexity of EBV gene expression and
demonstrate a new regulatory mechanism that invokes down-
stream activator and repressor elements not previously re-
ported in EBV genes. The coordinate regulation of Fp by both
EBNA-1 and E2F suggests a new way in which the virus may
subvert use of cell cycle regulatory factors to bring about
ordered replication of episomes. It now becomes of consider-
able interest to determine whether EBNA-1 action in oriP uses
a parallel mechanism that also invokes cellular proteins such as
the OBP-1 protein, recently described by Wen et al. (64), or
others not yet identified.
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